uniQure Reports Q1 2026 Financial Results with Increased Net Loss and Revenue Growth

uniQure N.V. reported its financial results for the first quarter of 2026, revealing a net loss of $53.5 million, an increase from a loss of $43.6 million in the same period last year. The company's total revenues for the quarter reached $3.6 million, a significant rise from $1.6 million in the first quarter of 2025, primarily driven by increased license revenues from CSL Behring related to HEMGENIX® sales. Operating expenses also rose, totaling $49.5 million compared to $47.2 million in the prior year, with notable increases in selling, general, and administrative expenses, which jumped to $20.1 million from $10.9 million.

In terms of operational metrics, uniQure's cash and cash equivalents, along with investment securities, amounted to $586.6 million as of March 31, 2026, down from $622.5 million at the end of 2025. The company reported a decrease in accounts receivable, which fell to $3.6 million from $5.9 million, reflecting a reduction in outstanding payments from CSL Behring. The total number of ordinary shares outstanding increased to 63,067,485 as of May 1, 2026, compared to 62,336,717 at the end of 2025.

Strategically, uniQure has been advancing its clinical pipeline, particularly with its lead candidate AMT-130 for Huntington's disease. The company is currently conducting Phase I/II clinical trials in the U.S. and Europe, with recent positive topline data indicating a significant slowing of disease progression in treated patients. However, the company faces challenges in securing regulatory approval, as the FDA has recommended a randomized, controlled study to support a Biologics License Application (BLA). In April 2026, uniQure also announced the termination of its supply obligations under the Genezen commercial supply agreement, which is expected to streamline its operations.

Looking ahead, uniQure anticipates that its current cash reserves will be sufficient to fund operations into the second half of 2029, covering ongoing clinical trials and potential commercialization efforts for AMT-130. However, the company acknowledges the need for additional funding, which may come from various sources, including public equity offerings and collaborations. The company remains focused on advancing its gene therapy pipeline while managing its financial resources amid ongoing clinical and regulatory developments.